Drug Trial Radar · NCT07144852
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Nov 29, 2025
Primary completion
Jan 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3, randomized, multi-center, evaluator-blind, vehicle-controlled study evaluates the efficacy and safety of reformulated Levulan Kerastick (aminolevulinic acid HCl 20%) combined with photodynamic therapy (PDT) for field-directed treatment of actinic keratosis (AK) on the upper extremities. Approximately 260 adult patients with 4-8 mild to moderate AK lesions on one arm will be randomized to receive either active treatment or vehicle control, followed by exposure to blue light. During the study, up to 2 PDT sessions may be administered depending on the clearance of lesions. The primary endpoint is complete clearance rate (CCR) at Week 12. Secondary endpoints include AK clearance rate (AKCR), partial clearance, change in total lesion count and area, recurrence rate, cosmetic response, and patient satisfaction. Safety assessments include adverse events, local skin reactions, vital signs, and lab tests.
Conditions
- Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Drug
Solution for topical use
VehicleOther
Solution for topical use
Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.Device
BLU-U® blue light PDT illuminator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Clearance Rate (CCR) i.e., proportion of patients achieving complete clearance of all AK lesions in the Treatment Area)Time frame: Week 12
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Medical Dermatology Specialist
Phoenix, Arizona · Recruiting
Center for Dermatology Clinical Research, Inc
Fremont, California · Recruiting
Clarity Dermatology, PLLC
Castle Rock, Colorado · Recruiting
Center for Clinical and Cosmetic Research
Aventura, Florida · Recruiting
Ziaderm Research LLC
North Miami Beach, Florida · Recruiting
Northwest Clinical Trials, Inc.
Boise, Idaho · Recruiting
Arlington Dermatology
Rolling Meadows, Illinois · Recruiting
The Indiana Clinical Trials Center, PC
Plainfield, Indiana · Recruiting
Dermatologic Surgery Center of Washington
Chevy Chase, Maryland · Recruiting
Minnesota Clinical Study Center
New Brighton, Minnesota · Recruiting
Medisearch, LLC
Saint Joseph, Missouri · Recruiting
Onsite Clinical Solutions, LLC
Huntersville, North Carolina · Recruiting
Oregon Dermatology and Research Center
Portland, Oregon · Recruiting
Dermatology Associates of Plymouth Meeting
Plymouth Meeting, Pennsylvania · Recruiting
Palmetto Clinical Trial Services, LLC
Anderson, South Carolina · Recruiting
Palmetto Clinical Trial Services, LLC
Greenville, South Carolina · Recruiting
Dermatology Associates of Knoxville
Knoxville, Tennessee · Recruiting
Tennessee Clinical Research Center
Nashville, Tennessee · Recruiting
J&S Studies, Inc
College Station, Texas · Recruiting
Pflugerville Dermatology Clinical Research Center, Inc. d/b/a Austin Institute for Clinical Research
Pflugerville, Texas · Recruiting
Dermatology of Seattle & Bellevue
Burien, Washington · Recruiting
Premier Clinical Research
Spokane, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.